Is there any diagnostic value of serum caveolin-1 levels on the determination of pancreatic adenocarcinoma?

Caveolin-1 (CAV-1) is a vital component in cancer pathogenesis, as its expression determines the survival of patients with cancer. This study investigates CAV-1 serum levels in pancreatic adenocarcinoma (PA) patients and their role in tumor progression and prognostic factors. The trial included 33 p...

Full description

Saved in:
Bibliographic Details
Published in:Journal of cancer research and therapeutics 2024-01
Main Authors: Karabulut, Senem, Afsar, Cigdem U, Paksoy, Nail, Ferhatoglu, Ferhat, Dogan, Izzet, Tastekin, Didem
Format: Article
Language:English
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c1393-994b42872383c31d60f3d1fef153cc1d7a77feb34c753f6e5df646ad30899bad3
container_end_page
container_issue
container_start_page
container_title Journal of cancer research and therapeutics
container_volume
creator Karabulut, Senem
Afsar, Cigdem U
Paksoy, Nail
Ferhatoglu, Ferhat
Dogan, Izzet
Tastekin, Didem
description Caveolin-1 (CAV-1) is a vital component in cancer pathogenesis, as its expression determines the survival of patients with cancer. This study investigates CAV-1 serum levels in pancreatic adenocarcinoma (PA) patients and their role in tumor progression and prognostic factors. The trial included 33 patients with pathologically confirmed pancreatic cancer (PC). The enzyme-linked immunosorbent assay (ELISA) method was used to measure the concentrations of CAV-1 in the blood. The study also included 20 healthy subjects. The statistical analysis was two-sided, and a P value of ≤ 0.05 was determined as statistically significant. The median age of the subjects was 59 years (32-84 years) at the time of diagnosis. There were 13 (39%) female participants. In 21 (63%) patients, the primary focus was the pancreatic head. In 23 stage IV patients, hepatic metastasis (n = 19, 83%) was observed. Only one patient (3%) was still alive at the end of the study period. Palliative chemotherapy (CTx) was provided, with 39% of the 23 patients responding to it. The overall survival (OS) rate in this cohort was 41.3 ± 8.3 weeks at a 95% confidence interval (CI), after 25-58 weeks. Serum baseline CAV-1 values among patients with PA were significantly higher compared with controls (p = 0.009). Patients with poor performance status, a pancreatic head tumor, lower albumin levels, higher serum carcinoembryonic antigen (CEA) levels, and higher CA 19.9 levels had significantly higher serum CAV-1 levels (p = 0.01, P = 0.05, P = 0.03, P = 0.02, and P = 0.04, respectively). However, CAV-1 did not show any prognostic value (p = 0.75). Although serum CAV-1 is a useful diagnostic marker in PC patients, it is not a prognostic or predictive marker.
doi_str_mv 10.4103/jcrt.jcrt_469_23
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2918198931</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2918198931</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1393-994b42872383c31d60f3d1fef153cc1d7a77feb34c753f6e5df646ad30899bad3</originalsourceid><addsrcrecordid>eNpNkD1PwzAURS0EoqWwMyGPLCl2npvYE0KIj0qVWGCOXPsZUhK72Eml_ntSWhDLu9LTuXc4hFxyNhWcwc3KxG66O5UoVJXDERlzpWQmOMhjMmaqhIwLmY_IWUorxmZlnstTMgKZF1yAGJPPeaLdB0ak2m-prfW7D6mrDd3opkcaHE0Y-5YavcHQ1D7jtMENNokGvytSix3Gtva6q4fPwK-1NxH1bkNb9MHoaGofWn17Tk6cbhJeHHJC3h4fXu-fs8XL0_z-bpEZDgoypcRS5LLMQYIBbgvmwHKHjs_AGG5LXZYOlyBMOQNX4My6QhTaApNKLYeckOv97jqGrx5TV7V1Mtg02mPoU5UrLrmSCviAsj1qYkgpoqvWsW513FacVTvF1Y_df4qHytVhvV-2aP8Kv07hG8xVe1c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2918198931</pqid></control><display><type>article</type><title>Is there any diagnostic value of serum caveolin-1 levels on the determination of pancreatic adenocarcinoma?</title><source>Publicly Available Content Database</source><creator>Karabulut, Senem ; Afsar, Cigdem U ; Paksoy, Nail ; Ferhatoglu, Ferhat ; Dogan, Izzet ; Tastekin, Didem</creator><creatorcontrib>Karabulut, Senem ; Afsar, Cigdem U ; Paksoy, Nail ; Ferhatoglu, Ferhat ; Dogan, Izzet ; Tastekin, Didem</creatorcontrib><description>Caveolin-1 (CAV-1) is a vital component in cancer pathogenesis, as its expression determines the survival of patients with cancer. This study investigates CAV-1 serum levels in pancreatic adenocarcinoma (PA) patients and their role in tumor progression and prognostic factors. The trial included 33 patients with pathologically confirmed pancreatic cancer (PC). The enzyme-linked immunosorbent assay (ELISA) method was used to measure the concentrations of CAV-1 in the blood. The study also included 20 healthy subjects. The statistical analysis was two-sided, and a P value of ≤ 0.05 was determined as statistically significant. The median age of the subjects was 59 years (32-84 years) at the time of diagnosis. There were 13 (39%) female participants. In 21 (63%) patients, the primary focus was the pancreatic head. In 23 stage IV patients, hepatic metastasis (n = 19, 83%) was observed. Only one patient (3%) was still alive at the end of the study period. Palliative chemotherapy (CTx) was provided, with 39% of the 23 patients responding to it. The overall survival (OS) rate in this cohort was 41.3 ± 8.3 weeks at a 95% confidence interval (CI), after 25-58 weeks. Serum baseline CAV-1 values among patients with PA were significantly higher compared with controls (p = 0.009). Patients with poor performance status, a pancreatic head tumor, lower albumin levels, higher serum carcinoembryonic antigen (CEA) levels, and higher CA 19.9 levels had significantly higher serum CAV-1 levels (p = 0.01, P = 0.05, P = 0.03, P = 0.02, and P = 0.04, respectively). However, CAV-1 did not show any prognostic value (p = 0.75). Although serum CAV-1 is a useful diagnostic marker in PC patients, it is not a prognostic or predictive marker.</description><identifier>ISSN: 0973-1482</identifier><identifier>EISSN: 1998-4138</identifier><identifier>DOI: 10.4103/jcrt.jcrt_469_23</identifier><identifier>PMID: 38261434</identifier><language>eng</language><publisher>India</publisher><ispartof>Journal of cancer research and therapeutics, 2024-01</ispartof><rights>Copyright © 2024 Copyright: © 2024 Journal of Cancer Research and Therapeutics.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c1393-994b42872383c31d60f3d1fef153cc1d7a77feb34c753f6e5df646ad30899bad3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,786,790,27957,27958,37048</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38261434$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Karabulut, Senem</creatorcontrib><creatorcontrib>Afsar, Cigdem U</creatorcontrib><creatorcontrib>Paksoy, Nail</creatorcontrib><creatorcontrib>Ferhatoglu, Ferhat</creatorcontrib><creatorcontrib>Dogan, Izzet</creatorcontrib><creatorcontrib>Tastekin, Didem</creatorcontrib><title>Is there any diagnostic value of serum caveolin-1 levels on the determination of pancreatic adenocarcinoma?</title><title>Journal of cancer research and therapeutics</title><addtitle>J Cancer Res Ther</addtitle><description>Caveolin-1 (CAV-1) is a vital component in cancer pathogenesis, as its expression determines the survival of patients with cancer. This study investigates CAV-1 serum levels in pancreatic adenocarcinoma (PA) patients and their role in tumor progression and prognostic factors. The trial included 33 patients with pathologically confirmed pancreatic cancer (PC). The enzyme-linked immunosorbent assay (ELISA) method was used to measure the concentrations of CAV-1 in the blood. The study also included 20 healthy subjects. The statistical analysis was two-sided, and a P value of ≤ 0.05 was determined as statistically significant. The median age of the subjects was 59 years (32-84 years) at the time of diagnosis. There were 13 (39%) female participants. In 21 (63%) patients, the primary focus was the pancreatic head. In 23 stage IV patients, hepatic metastasis (n = 19, 83%) was observed. Only one patient (3%) was still alive at the end of the study period. Palliative chemotherapy (CTx) was provided, with 39% of the 23 patients responding to it. The overall survival (OS) rate in this cohort was 41.3 ± 8.3 weeks at a 95% confidence interval (CI), after 25-58 weeks. Serum baseline CAV-1 values among patients with PA were significantly higher compared with controls (p = 0.009). Patients with poor performance status, a pancreatic head tumor, lower albumin levels, higher serum carcinoembryonic antigen (CEA) levels, and higher CA 19.9 levels had significantly higher serum CAV-1 levels (p = 0.01, P = 0.05, P = 0.03, P = 0.02, and P = 0.04, respectively). However, CAV-1 did not show any prognostic value (p = 0.75). Although serum CAV-1 is a useful diagnostic marker in PC patients, it is not a prognostic or predictive marker.</description><issn>0973-1482</issn><issn>1998-4138</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpNkD1PwzAURS0EoqWwMyGPLCl2npvYE0KIj0qVWGCOXPsZUhK72Eml_ntSWhDLu9LTuXc4hFxyNhWcwc3KxG66O5UoVJXDERlzpWQmOMhjMmaqhIwLmY_IWUorxmZlnstTMgKZF1yAGJPPeaLdB0ak2m-prfW7D6mrDd3opkcaHE0Y-5YavcHQ1D7jtMENNokGvytSix3Gtva6q4fPwK-1NxH1bkNb9MHoaGofWn17Tk6cbhJeHHJC3h4fXu-fs8XL0_z-bpEZDgoypcRS5LLMQYIBbgvmwHKHjs_AGG5LXZYOlyBMOQNX4My6QhTaApNKLYeckOv97jqGrx5TV7V1Mtg02mPoU5UrLrmSCviAsj1qYkgpoqvWsW513FacVTvF1Y_df4qHytVhvV-2aP8Kv07hG8xVe1c</recordid><startdate>20240122</startdate><enddate>20240122</enddate><creator>Karabulut, Senem</creator><creator>Afsar, Cigdem U</creator><creator>Paksoy, Nail</creator><creator>Ferhatoglu, Ferhat</creator><creator>Dogan, Izzet</creator><creator>Tastekin, Didem</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20240122</creationdate><title>Is there any diagnostic value of serum caveolin-1 levels on the determination of pancreatic adenocarcinoma?</title><author>Karabulut, Senem ; Afsar, Cigdem U ; Paksoy, Nail ; Ferhatoglu, Ferhat ; Dogan, Izzet ; Tastekin, Didem</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1393-994b42872383c31d60f3d1fef153cc1d7a77feb34c753f6e5df646ad30899bad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Karabulut, Senem</creatorcontrib><creatorcontrib>Afsar, Cigdem U</creatorcontrib><creatorcontrib>Paksoy, Nail</creatorcontrib><creatorcontrib>Ferhatoglu, Ferhat</creatorcontrib><creatorcontrib>Dogan, Izzet</creatorcontrib><creatorcontrib>Tastekin, Didem</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of cancer research and therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Karabulut, Senem</au><au>Afsar, Cigdem U</au><au>Paksoy, Nail</au><au>Ferhatoglu, Ferhat</au><au>Dogan, Izzet</au><au>Tastekin, Didem</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is there any diagnostic value of serum caveolin-1 levels on the determination of pancreatic adenocarcinoma?</atitle><jtitle>Journal of cancer research and therapeutics</jtitle><addtitle>J Cancer Res Ther</addtitle><date>2024-01-22</date><risdate>2024</risdate><issn>0973-1482</issn><eissn>1998-4138</eissn><notes>ObjectType-Article-1</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-2</notes><notes>content type line 23</notes><abstract>Caveolin-1 (CAV-1) is a vital component in cancer pathogenesis, as its expression determines the survival of patients with cancer. This study investigates CAV-1 serum levels in pancreatic adenocarcinoma (PA) patients and their role in tumor progression and prognostic factors. The trial included 33 patients with pathologically confirmed pancreatic cancer (PC). The enzyme-linked immunosorbent assay (ELISA) method was used to measure the concentrations of CAV-1 in the blood. The study also included 20 healthy subjects. The statistical analysis was two-sided, and a P value of ≤ 0.05 was determined as statistically significant. The median age of the subjects was 59 years (32-84 years) at the time of diagnosis. There were 13 (39%) female participants. In 21 (63%) patients, the primary focus was the pancreatic head. In 23 stage IV patients, hepatic metastasis (n = 19, 83%) was observed. Only one patient (3%) was still alive at the end of the study period. Palliative chemotherapy (CTx) was provided, with 39% of the 23 patients responding to it. The overall survival (OS) rate in this cohort was 41.3 ± 8.3 weeks at a 95% confidence interval (CI), after 25-58 weeks. Serum baseline CAV-1 values among patients with PA were significantly higher compared with controls (p = 0.009). Patients with poor performance status, a pancreatic head tumor, lower albumin levels, higher serum carcinoembryonic antigen (CEA) levels, and higher CA 19.9 levels had significantly higher serum CAV-1 levels (p = 0.01, P = 0.05, P = 0.03, P = 0.02, and P = 0.04, respectively). However, CAV-1 did not show any prognostic value (p = 0.75). Although serum CAV-1 is a useful diagnostic marker in PC patients, it is not a prognostic or predictive marker.</abstract><cop>India</cop><pmid>38261434</pmid><doi>10.4103/jcrt.jcrt_469_23</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0973-1482
ispartof Journal of cancer research and therapeutics, 2024-01
issn 0973-1482
1998-4138
language eng
recordid cdi_proquest_miscellaneous_2918198931
source Publicly Available Content Database
title Is there any diagnostic value of serum caveolin-1 levels on the determination of pancreatic adenocarcinoma?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-21T18%3A00%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20there%20any%20diagnostic%20value%20of%20serum%20caveolin-1%20levels%20on%20the%20determination%20of%20pancreatic%20adenocarcinoma?&rft.jtitle=Journal%20of%20cancer%20research%20and%20therapeutics&rft.au=Karabulut,%20Senem&rft.date=2024-01-22&rft.issn=0973-1482&rft.eissn=1998-4138&rft_id=info:doi/10.4103/jcrt.jcrt_469_23&rft_dat=%3Cproquest_cross%3E2918198931%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1393-994b42872383c31d60f3d1fef153cc1d7a77feb34c753f6e5df646ad30899bad3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2918198931&rft_id=info:pmid/38261434&rfr_iscdi=true